NO874352L - Fremstilling av legemiddelblandinger stabilisert mot oksydasjon. - Google Patents

Fremstilling av legemiddelblandinger stabilisert mot oksydasjon.

Info

Publication number
NO874352L
NO874352L NO874352A NO874352A NO874352L NO 874352 L NO874352 L NO 874352L NO 874352 A NO874352 A NO 874352A NO 874352 A NO874352 A NO 874352A NO 874352 L NO874352 L NO 874352L
Authority
NO
Norway
Prior art keywords
compounds
preparation
ascorbic acid
mixtures
group
Prior art date
Application number
NO874352A
Other languages
English (en)
Norwegian (no)
Other versions
NO874352D0 (no
Inventor
Kuchi Sury Murthy
Michael Ray Harris
Gerard Clifford Hokanson
Robert George Reisch Jr
Mahdi Bakir Fawzi
Frank Stanley Waldman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25445868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO874352(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO874352D0 publication Critical patent/NO874352D0/no
Publication of NO874352L publication Critical patent/NO874352L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO874352A 1986-10-20 1987-10-19 Fremstilling av legemiddelblandinger stabilisert mot oksydasjon. NO874352L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/921,717 US4830853A (en) 1986-10-20 1986-10-20 Drug compositions stabilized against oxidation

Publications (2)

Publication Number Publication Date
NO874352D0 NO874352D0 (no) 1987-10-19
NO874352L true NO874352L (no) 1988-04-21

Family

ID=25445868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO874352A NO874352L (no) 1986-10-20 1987-10-19 Fremstilling av legemiddelblandinger stabilisert mot oksydasjon.

Country Status (20)

Country Link
US (1) US4830853A (de)
EP (1) EP0264887B1 (de)
JP (1) JP2703906B2 (de)
KR (1) KR960000430B1 (de)
AT (1) ATE67090T1 (de)
AU (1) AU604061B2 (de)
CA (1) CA1297024C (de)
DE (1) DE3772924D1 (de)
DK (1) DK174916B1 (de)
ES (1) ES2040726T3 (de)
FI (1) FI100091B (de)
GR (1) GR3002698T3 (de)
HK (1) HK85694A (de)
IE (1) IE60773B1 (de)
NO (1) NO874352L (de)
NZ (1) NZ221954A (de)
PH (1) PH25582A (de)
PT (1) PT85942B (de)
SG (1) SG95494G (de)
ZA (1) ZA877132B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
YU48602B (sh) * 1991-11-25 1998-12-23 Krka Tovarna Zdravil P.O. Postupak za dobijanje stabilne formulacije soli enalaprila
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
PT1121103E (pt) 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
CA2330581A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
AU2003201071A1 (en) * 2002-01-15 2003-07-30 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
DK1635792T3 (da) * 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
EP1694308A1 (de) * 2003-10-30 2006-08-30 Lupin Ltd. Stabile formulierungen von ace-hemmern und herstellungsverfahren dafür
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
RU2008145115A (ru) * 2006-04-19 2010-05-27 Тева Фармасьютикл Индастриес Лтд. (Il) Стабильные фармацевтические композиции производственных соединений 2-аза-бицикло[3.3.0]-октан-3-карбоновой кислоты
US8017168B2 (en) * 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
KR100808132B1 (ko) 2007-03-02 2008-02-29 고천일 음식물쓰레기 소멸처리장치
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
SI2654729T1 (sl) * 2010-12-24 2016-08-31 Krka, D.D., Novo Mesto Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
TR201819662T4 (tr) 2014-07-31 2019-01-21 Pharmathen Sa Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US20180325813A1 (en) 2015-11-07 2018-11-15 Ftf Pharma Private Limited Oral solution of ace inhibitors
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CA3086022A1 (en) 2018-01-11 2019-07-18 Meritage Pharma, Inc. Stable corticosteroid compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (de) * 1957-07-17
US3697641A (en) * 1970-01-02 1972-10-10 Gerhard W Ahrens Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate
EP0045238B1 (de) * 1980-07-29 1986-10-01 Sanofi S.A. Durch Säure stabilisierte Mischungen von Thienopyridinderivaten und Verfahren zum Verhindern der Zersetzung solcher Verbindungen
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4442089A (en) * 1982-07-06 1984-04-10 E. R. Squibb & Sons, Inc. Method for treating glaucoma with topical or systemic ACE inhibitor compositions
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration

Also Published As

Publication number Publication date
JPS63104931A (ja) 1988-05-10
PT85942A (en) 1987-11-01
KR960000430B1 (ko) 1996-01-06
HK85694A (en) 1994-08-26
SG95494G (en) 1994-10-28
ATE67090T1 (de) 1991-09-15
EP0264887A1 (de) 1988-04-27
FI874594L (fi) 1988-04-21
CA1297024C (en) 1992-03-10
AU604061B2 (en) 1990-12-06
NZ221954A (en) 1990-03-27
EP0264887B1 (de) 1991-09-11
FI100091B (fi) 1997-09-30
AU7939787A (en) 1988-04-21
ES2040726T3 (es) 1993-11-01
US4830853A (en) 1989-05-16
JP2703906B2 (ja) 1998-01-26
KR880004811A (ko) 1988-06-27
DK543587D0 (da) 1987-10-16
FI874594A0 (fi) 1987-10-19
GR3002698T3 (en) 1993-01-25
DE3772924D1 (de) 1991-10-17
NO874352D0 (no) 1987-10-19
PH25582A (en) 1991-08-08
IE60773B1 (en) 1994-08-10
IE872550L (en) 1988-04-20
ZA877132B (en) 1989-04-26
DK174916B1 (da) 2004-02-23
PT85942B (pt) 1990-07-31
DK543587A (da) 1988-04-21

Similar Documents

Publication Publication Date Title
DK174916B1 (da) Farmaceutisk sammensætning og fremgangsmåde til at stabilisere denne
DK174976B1 (da) Farmaceutiske sammensætning og fremgangsmåde til stabilisering af et ACE inhibitormedikament
US4743450A (en) Stabilized compositions
EP0464084B1 (de) Verwendung von eicosapentaensäure zur behandlung der kachexie
PL190293B1 (pl) Sposób stabilizowania naloksonu i jego soli, stały półstały lub ciekły lek, zawierający nalokson i jego sole oraz zastosowanie środków stabilizujących do zapobiegania dimeryzacji naloksonu
JPH04230220A (ja) 医薬組成物
SI9200404A (en) Pharmaceutical composition and process for the preparation thereof
NO323229B1 (no) Flytende eller faste farmasoytiske preparater inneholdende cilansetron stabilisert mot racemisering, anvendelse av sure tilsetningsstoffer til stabiliseringen og fremgangsmate for fremstilling av slike faste preparater
JPH0152366B2 (de)
IE71022B1 (en) Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamides containing preparation and stabilizing method therefor
EP0038060B1 (de) Pharmazeutische Zusammensetzung mit Gehalt an L-alpha-Methyl-3,4-dihydroxyphenylalanin und Salicylamid zur Behandlung hohen Blutdrucks
EP0024868A1 (de) Schistosomizide Zusammensetzung enthaltend Oxamniquine und Praziquantel
US3721738A (en) Treatment and prophylaxis of thrombovascular diseases with 2-imidazolone derivatives
EP0302097B1 (de) Pharmazeutische zusammensetzungen zur behandlung der verstopfung der luftwege
ZA200500064B (en) Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
DE2643303A1 (de) Hypoglykaemisch wirksames arzneimittel
US3012938A (en) Inhibition of isoniazid acetylation
JPH0526766B2 (de)
KR20110133345A (ko) 비쑥 추출물을 포함하는 에이디피-리보실 사이클라제 활성을 저해하는 억제제
WO1996022096A1 (en) Pharmaceutical compositions containing bisaramil inhibiting radical production and process for preparing same